Trial Profile
A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Bone metastases; Brain metastases; Triple negative breast cancer
- Focus Therapeutic Use
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 29 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.
- 29 Aug 2018 Status changed from recruiting to active, no longer recruiting.